Literature DB >> 2752507

Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

P A Reece1, I Stafford, M Davy, R Morris, S Freeman.   

Abstract

The disposition of unchanged cisplatin in ten patients with ovarian cancer receiving 2-h infusions of 100 mg/m2 was compared with that of ten patients receiving 6-h infusions. A high-performance liquid chromatographic assay specific for the unchanged drug was used and all collected samples were rapidly processed. Patients were catheterized for urine collections. Cisplatin renal clearance was significantly lower after 6-hour infusions (52.8 +/- 16.2 ml/min per m2) than after 2-h infusions (87.1 +/- 38.2 ml/min per m2) (P = 0.026). Total clearance was also lower and less variable, although not significantly, in patients receiving the longer infusion. No differences in nonrenal clearance, volume of distribution, or half-life were observed between the two groups. There was only a poor relationship between cisplatin renal clearance and creatinine clearance after 2-h (r2 = 0.02; P = 0.66) and 6-h infusions (r2 = 0.18; P = 0.23). A single cisplatin plasma level obtained at the end of the infusion proved to be a good predictor of total cisplatin clearance after both 2-h (r2 = 0.70; P = 0.0096) and 6-h infusions (r2 = 0.97; P = 0.0001). This level was not significantly related to the relatively small changes in creatinine clearance that occurred after three courses of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752507     DOI: 10.1007/bf00257629

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Post-column reaction detector for platinum(II) antineoplastic agents.

Authors:  K C Marsh; L A Sternson; A J Repta
Journal:  Anal Chem       Date:  1984-03       Impact factor: 6.986

2.  High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.

Authors:  D R Gandara; M W DeGregorio; H Wold; B J Wilbur; M Kohler; H J Lawrence; A B Deisseroth; C B George
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

3.  Phase I study of continuous-infusion cisplatin.

Authors:  M R Posner; A T Skarin; J Clark; T J Ervin
Journal:  Cancer Treat Rep       Date:  1986-07

4.  Disposition of unchanged cisplatin in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; S Freeman
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

5.  Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity.

Authors:  P Salem; M Khalyl; K Jabboury; L Hashimi
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

6.  Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.

Authors:  J J Lokich
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

7.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  The effect of administration rate on cisplatin-induced emesis.

Authors:  N S Jordan; P K Schauer; A Schauer; C Nightingale; G Golub; R S Martin; H M Williams
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

9.  Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.

Authors:  J F Belliveau; M R Posner; L Ferrari; G W Crabtree; F J Cummings; M C Wiemann; G P O'Leary; H Griffin; M A Phaneuf; A O'Rourke
Journal:  Cancer Treat Rep       Date:  1986-10

10.  Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; H E Gall; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11
View more
  4 in total

1.  Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2008-11-15       Impact factor: 2.953

2.  Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.

Authors:  V C Sileni; V Fosser; P Maggian; E Padula; M Beltrame; M Nicolini; P Arslan
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig.

Authors:  G Laurell; A Andersson; B Engström; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.

Authors:  N Nagai; K Hotta; H Yamamura; H Ogata
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.